Since the discovery of the first probiotic drug, Saccharomyces boulardii CNCM I-745® in 1953, Biocodex has evolved from a pioneer to an international key player in the microbiota realm.
At Biocodex we have devoted this expertise to nurturing and elevating the importance of the human microbiota on our health. We believe that understanding and acting on microbiota is part of the future of human health,
and we are committed to realizing our mission and to improving the quality of life of individuals worldwide. We provide solutions like high quality probiotic products, we educate healthcare professionals on the growing importance of microbiota on well-being and fund academic researches through Biocodex Microbiota Foundation.
Biocodex acquired Laboratories Iprad in 2020. Biocodex have now also complementary product portfolios in the field of feminine care market. The first products will be seen in Nordics in near future.
Our Business model
Our Biocodex Nordics unique business model offers an extensive service portfolio. We import and market hospital and OTC pharmaceuticals, as well as free trade products. We also provide comprehensive range of pharmaceutical and medical services including auditing, regulatory and pharmacovigilance services. Besides our own products, Biocodex Nordics represents 16 international pharmaceutical companies and offers pharmaceutical and medical services to over 100 customers worldwide.
At the heart of our success Biocodex depends on the engagement, passion and conviction of the people who enable us to make progress toward our vision. We place a high priority on employee development and quality of life to create an inspiring, challenging and humanistic workplace.
Want to know more?
Biocodex operates in more than 120 countries where we anchor our operations through robust partnerships and by creating our own operational footprint through 20 subsidiaries around the world. Biocodex’s 1,530 employees are committed to serving millions of patients around the world. We apply our expertise to a wide range of products to meet patient needs, focusing on three pillars: the Microbiota Mission, orphan drugs and women’s health.
Biocodex is a family-owned pharmaceutical company that has grown from a French microbiota pioneer in the 1950s to an international pharmaceutical player today by diversifying its products and expanding its geographical footprint. We offer health solutions to patients in more than 120 countries through our own operations or long-term partnerships.